Specific induced pluripotent stem cell line containing CLCN2 homozygous mutation for leukoencephalopathy patients
A technology of pluripotent stem cells and leukoencephalopathy, applied in the field of specific induced pluripotent stem cell lines and construction of leukoencephalopathy patients, can solve the problems of unclear pathogenic mechanism and no effective treatment methods
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0040] 1. Urine cell isolation culture and reprogramming
[0041] ①The patient was a 38-year-old female with intention tremor of both hands, memory loss, tinnitus, and vision loss; physical examination revealed cerebellar ataxia; brain MRI revealed abnormal T1 in the white matter of the internal capsule, cerebral peduncle, and middle cerebellar peduncle The weighted images were hypointense, and the T2-weighted images were hyperintense. Subsequent Sanger sequencing confirmed that there was a homozygous pathogenic mutation in the CLCN2 gene (Exon20:c.2257C>T; p.Arg753Ter). This case met the diagnostic criteria for CC2L.
[0042] Cells: urine cells from patients with CC2L
[0043] ②Reagents and consumables:
[0044] 1) DMEM / Ham's F-12 nutrient mix (1:1): STEMCELL Technologies, #05851
[0045] 2) FBS: Natocor, #SFBE
[0046] 3) Renal epithelial cell growth medium (REGM) supplement: Lonza, #CC-4127
[0047] 4) TrypLE express: Life technologies, #12604013
[0048] 5) Double an...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com